Momeni F, Shahbazi-Gahrouei D, Mahmoudi T, Mehdizadeh A
Diagnostics (Basel). 2025; 15(3).
PMID: 39941290
PMC: 11817314.
DOI: 10.3390/diagnostics15030360.
Kim H, Kwon M, Jo S, Park J, Kim J, Kim J
Sci Rep. 2024; 14(1):10083.
PMID: 38698190
PMC: 11066072.
DOI: 10.1038/s41598-024-60843-8.
Arvidsson I, Strandberg O, Palmqvist S, Stomrud E, Cullen N, Janelidze S
Alzheimers Res Ther. 2024; 16(1):61.
PMID: 38504336
PMC: 10949809.
DOI: 10.1186/s13195-024-01428-5.
Naude J, Wang M, Leon R, Smith E, Ismail Z
medRxiv. 2024; .
PMID: 38405711
PMC: 10888987.
DOI: 10.1101/2024.02.11.24302665.
Burnham S, Iaccarino L, Pontecorvo M, Fleisher A, Lu M, Collins E
Brain Commun. 2024; 6(1):fcad305.
PMID: 38187878
PMC: 10768888.
DOI: 10.1093/braincomms/fcad305.
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer's disease in patients with mild cognitive symptoms.
Arvidsson I, Strandberg O, Palmqvist S, Stomrud E, Cullen N, Janelidze S
Res Sq. 2023; .
PMID: 37986841
PMC: 10659533.
DOI: 10.21203/rs.3.rs-3569391/v1.
Tau: a biomarker of Huntington's disease.
Lepinay E, Cicchetti F
Mol Psychiatry. 2023; 28(10):4070-4083.
PMID: 37749233
DOI: 10.1038/s41380-023-02230-9.
Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints.
Lu J, Ma X, Zhang H, Xiao Z, Li M, Wu J
Transl Neurodegener. 2023; 12(1):34.
PMID: 37381042
PMC: 10308642.
DOI: 10.1186/s40035-023-00365-x.
Distinct resting-state functional connectivity patterns of Anterior Insula affected by smoking in mild cognitive impairment.
Zhang T, Zeng Q, Li K, Liu X, Fu Y, Qiu T
Brain Imaging Behav. 2023; 17(4):386-394.
PMID: 37243752
PMC: 10435406.
DOI: 10.1007/s11682-023-00766-6.
The Sensitivity of Tau Tracers for the Discrimination of Alzheimer's Disease Patients and Healthy Controls by PET.
Mohammadi Z, Alizadeh H, Marton J, Cumming P
Biomolecules. 2023; 13(2).
PMID: 36830659
PMC: 9953528.
DOI: 10.3390/biom13020290.
Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease.
Dang M, Chen Q, Zhao X, Chen K, Li X, Zhang J
Hum Brain Mapp. 2023; 44(2):327-340.
PMID: 36647262
PMC: 9842886.
DOI: 10.1002/hbm.26043.
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.
Smith R, Cullen N, Binette A, Leuzy A, Blennow K, Zetterberg H
Alzheimers Dement. 2022; 19(6):2497-2507.
PMID: 36516028
PMC: 10264552.
DOI: 10.1002/alz.12875.
A Machine Learning-Based Approach to Discrimination of Tauopathies Using [ F]PM-PBB3 PET Images.
Endo H, Tagai K, Ono M, Ikoma Y, Oyama A, Matsuoka K
Mov Disord. 2022; 37(11):2236-2246.
PMID: 36054492
PMC: 9805085.
DOI: 10.1002/mds.29173.
Intraneuronal sortilin aggregation relative to granulovacuolar degeneration, tau pathogenesis and sorfra plaque formation in human hippocampal formation.
Jiang J, Yang C, Ai J, Zhang Q, Cai X, Tu T
Front Aging Neurosci. 2022; 14:926904.
PMID: 35978952
PMC: 9376392.
DOI: 10.3389/fnagi.2022.926904.
Tau positron emission tomography in preclinical Alzheimer's disease.
Insel P, Young C, Aisen P, Johnson K, Sperling R, Mormino E
Brain. 2022; 146(2):700-711.
PMID: 35962782
PMC: 10169284.
DOI: 10.1093/brain/awac299.
Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.
Tanner J, Iaccarino L, Edwards L, Asken B, Gorno-Tempini M, Kramer J
Brain. 2022; 145(12):4489-4505.
PMID: 35762829
PMC: 10200306.
DOI: 10.1093/brain/awac229.
Multimodal deep learning for Alzheimer's disease dementia assessment.
Qiu S, Miller M, Joshi P, Lee J, Xue C, Ni Y
Nat Commun. 2022; 13(1):3404.
PMID: 35725739
PMC: 9209452.
DOI: 10.1038/s41467-022-31037-5.
The Overlap Index as a Means of Evaluating Early Tau PET Signal Reliability.
Lee J, Burkett B, Min H, Lundt E, Albertson S, Botha H
J Nucl Med. 2022; 63(11):1748-1753.
PMID: 35301239
PMC: 9635680.
DOI: 10.2967/jnumed.121.263136.
Multiscale structural mapping of Alzheimer's disease neurodegeneration.
Jang I, Li B, Riphagen J, Dickerson B, Salat D
Neuroimage Clin. 2022; 33:102948.
PMID: 35121307
PMC: 8814667.
DOI: 10.1016/j.nicl.2022.102948.
Spatially resolved neural slowing predicts impairment and amyloid burden in Alzheimer's disease.
Wiesman A, Murman D, Losh R, Schantell M, Christopher-Hayes N, Johnson H
Brain. 2022; 145(6):2177-2189.
PMID: 35088842
PMC: 9246709.
DOI: 10.1093/brain/awab430.